Merck: BioInvent reveals solid data with its TNFR2 antibody BI-1808 and KEYTRUDA in advanced ovarian cancer at ASCO

[출처/시간] Briefing.com - 6:09 AM ET, 05/22/2026

BioInvent International announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer. These data will be presented in a poster (#2605) as part of the Developmental Therapeutics - Immunotherapy track at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019)56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatmentThe treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations